Results 171 to 180 of about 3,854,141 (349)

Beta-blockers after myocardial infarction: time to change the guidelines. [PDF]

Eur Heart J Cardiovasc Pharmacother
Jernberg T.
europepmc   +1 more source

Cyclic azapeptide CD36 ligand attenuates cardiac injury and reduces long‐chain fatty acid accumulation after myocardial ischemia–reperfusion in mice

FEBS Open Bio, EarlyView.
In a murine model of myocardial ischemia and reperfusion (MI/R), the CD36 azapeptide ligand MPE‐298 reduces cardiac injury and transiently lowers left ventricular long‐chain fatty acids (LCFAs) accumulation 3 h after reperfusion, accompanied by a decrease of oxidative stress and inflammation‐associated genes' expression in the heart and adipose tissue.
Jade Gauvin, Naghme Radmannia, David N. Huynh, Liliane Ménard, Caroline Daneault, Maïté Veilleux, Ahsanullah Ahsanullah, André C. Carpentier, William D. Lubell, Matthieu Ruiz, Huy Ong, Sylvie Marleau, Simon‐Pierre Gravel   +12 more
wiley   +1 more source

Efficacy of beta-blockers in the treatment of hematidrosis: A systematic review. [PDF]

World J Exp Med
Palabiyik AA.
europepmc   +1 more source

Beta-blockers in sepsis: time to reconsider current constraints?

British Journal of Anaesthesia, 2017
E. Boerma, M. Singer
semanticscholar   +1 more source

Emerging insights into CC and CXC chemokines and their receptors in Mycobacterium tuberculosis infection

FEBS Open Bio, EarlyView.
The dual roles of CC and CXC chemokines in distinguishing active, latent, and subclinical tuberculosis were reviewed, along with an evaluation of their potential as diagnostic biomarkers and therapeutic targets to advance precision medicine in tuberculosis management. The graphical abstract was generated with AI assistance (Gemini 3.0).
Xuying Yin, Dangsheng Xiao, Jiezuan Yang
wiley   +1 more source

Ventricular Tachycardia in the Absence of Structural Heart Disease [PDF]

In up to 10% of patients who present with ventricular tachycardia (VT), obvious structural heart disease is not identified. In such patients, causes of ventricular arrhythmia include right ventricular outflow tract (RVOT) VT, extrasystoles, idiopathic ...
Srivathsan, Komandoor, Lester, Steven J, Appleton, Christopher P, Scott, Luis R P, Munger, Thomas M   +4 more
core  

Impact of Disease-Specific Treatment and Non-Selective Beta Blockers on Risk of PVT in Cirrhotic Patients With HCV or PBC. [PDF]

Liver Int
Gonzalez HC, Gordon SC, Trudeau S, Wu T, Rupp L, Melkonian C, Schmidt MA, Daida YG, Sahota AK, Bowlus CL, Lu M.   +10 more
europepmc   +1 more source

BETA-BLOCKERS

By inhibiting β-adrenergic receptors, beta-blockers lower blood pressure and heart rate and are used to treat cardiovascular illnesses such as hypertension, angina, arrhythmias, and heart failure. Variations in these medications' oral absorption, distribution, hepatic metabolism, and renal excretion impact their therapeutic utility.
Zohaib, Tahir, Shehram, Qazafi, Muhammad Nauman, Asghar, Danish, Riaz, Umar, Ghani, Rimsha, Muzafar, Hassan, Jan, Babar Umar, Khan   +7 more
openaire   +2 more sources

Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent?

Heart Rhythm, 2017
M. Ackerman, S. Priori, A. Dubin, P. Kowey, N. Linker, D. Slotwiner, J. Triedman, G. V. Van Hare, M. Gold   +8 more
semanticscholar   +1 more source

Cutaneous Melanoma Drives Metabolic Changes in the Aged Bone Marrow Immune Microenvironment

Aging and Cancer, EarlyView.
Melanoma, the deadliest form of skin cancer, increasingly affects older adults. Our study reveals that melanoma induces changes in iron and lipid levels in the bone marrow, impacting immune cell populations and increasing susceptibility to ferroptosis.
Alexis E. Carey, Murilo Ramos Rocha, Cheyenne Palm, Vania Wang, Denys Balandin, Ethan Black, Kevin Y. Zhang, Fan Huang, Daniel J. Zabransky, Yash Chhabra, Mareike Peters, Gabriel Ghiaur, Ashani Weeraratna   +12 more
wiley   +1 more source